FDA approves olaparib/abiraterone combination for BRCA+ metastatic castration-resistant prostate cancer
The FDA has approved olaparib (Lynparza) plus abiraterone and prednisone or prednisolone for the treatment of patients with deleterious or suspected BRCA-mutated metastatic castration-resistant prostate cancer, as determined by an accompanying FDA-approved diagnostic test.1 The regulatory decision is supported by results from the Phase 3 PROpel study (NCT03732820) in which the olaparib regimen significantly improved … Read more